ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
The Regulation and Function of Hippo/YAP Pathway in Cancer.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting.Clinical and translational medicine · 2026Review
- Mechanobiology-Driven Metabolic Reprogramming: Integrative Roles of YAP/TAZ Signaling and Extracellular Matrix Dynamics.Cell biology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Hippo/YAP signaling pathway is a key regulatory network that governs organ size, tissue homeostasis, cell proliferation, and cell polarity. Aberrant Hippo/YAP signaling contributes to the initiation and progression of multiple cancers, making this pathway an attractive therapeutic target. Although several agents targeting Hippo/YAP have shown promise in preclinical models, clinical translation has been limited. These challenges likely stem from an incomplete understanding of the upstream regulators, downstream effectors, pathway crosstalk, and context-dependent roles of Hippo/YAP across different tumor types. Continued mechanistic investigation is required to clarify these complexities and reveal new therapeutic vulnerabilities. In this review, we summarize the current knowledge of the core components of the Hippo/YAP pathway, its regulatory mechanisms and interactions with other signaling cascades, its dysregulation in cancer, the involvement of microRNAs and lncRNAs in pathway modulation, and emerging therapeutic strategies targeting Hippo/YAP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.